Advertisement

Treatment of Post-Transplant B-Cell Lymphomas with Monoclonal Chimeric Anti-B-Cell Antibodies

  • J. L. Garnier
  • D. Glotz
  • J. Dantal
  • E. Alamartine
  • Y. Lebranchu
  • P. Deteix
  • G. T. Stevenson
Part of the Transplantation and Clinical Immunology book series (TRAC, volume 29)

Abstract

Treatment of post-transplant B-cell lymphomas has proved to be difficult because the decrease of the immunosuppressive therapy can lead to rejection and chemotherapy is hazardous. Anti-CD21/24 monoclonal antibody therapy has previously offered the advantages of a good tolerance and efficiency on oligoclonal lymphomas. With a better knowledge of the phenotype of post-transplant lymphomas, we tried to develop chimeric monoclonal antibodies (mAb) that could be more efficient on the lymphomas and could permit to keep the immunosuppression in order to avoid graft loss.

Keywords

Immunosuppressive Therapy Liver Graft Renal Graft Kidney Graft Chimeric Monoclonal Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • J. L. Garnier
    • 1
  • D. Glotz
  • J. Dantal
  • E. Alamartine
  • Y. Lebranchu
  • P. Deteix
  • G. T. Stevenson
    • 2
  1. 1.Hôpital Edouard HerriotLyonFrance
  2. 2.Tenovus LaboratorySouthampton HospitalUK

Personalised recommendations